SP Nutraceuticals | CEO-Led Commercialization & Business Transformation
Role: CEO, SP Nutraceuticals Inc. (role dates to be reconciled with the executive résumé before publication).
I led the development of a metabolic health business around AvoB, a patented bioactive, and Metavo, its consumer-facing brand—building commercial channels, advancing clinical and intellectual-property assets, and transforming the operating platform.
Strategy: Three Commercial Growth Platforms
I developed a five-year strategic plan and three complementary business channels: consumer packaged goods (CPG), branded ingredients, and a digital wellness operating system. The strategy sought to connect consumer products, ingredient commercialization and personalized wellness capabilities.
Capital Strategy & Investor Development
I led debt and equity fundraising efforts and investor engagement across venture capital, family offices, angel investors and crowdfunding channels. My executive résumé references $6 million in capital-raising activity; the amount actually closed, raised or pursued must be reconciled before this figure is presented as capital secured.
Metavo Brand & Product Commercialization
I led the Metavo rebrand, the development of 15 new products and expansion into the U.S. market, while building the foundation for broader AvoB ingredient commercialization.
Clinical Research & Intellectual Property
I funded and helped design a randomized controlled trial (RCT) for AvoB to support its scientific and intellectual-property strategy. The clinical RCT and preclinical SHIME work were completed, with manuscripts and publication work in progress. The existence of a completed study should not be confused with proof of efficacy for any particular endpoint; claims will follow the actual results and publication status.
I also worked to expand the IP and scientific asset base through patent development, clinical research, analytical standards and related bioactive research.
Digital Wellness Platform & Partnership
I secured a joint venture with Ingeni Health to develop a personalized health platform combining wearables, biomarker information and supplement/GLP-1-related wellness inputs, designed for potential use by retailers, practitioners and corporate wellness programs. This describes the partnership and proposed platform, not an assertion of full commercial deployment.
Operating & Digital Transformation
I reworked core business capabilities spanning contract manufacturing, logistics, agency partners, sales brokerage, legal support, technology systems, financial reporting and product development. The digital transformation included a new website, technology stack, advertising strategy, influencer programs and public relations.
Reported Operating Improvements
During the transformation period, my executive résumé reports a 10x increase in sales over two years, a 66% improvement in EBITDA, 20,000 points of distribution (TPDs), a 25x reduction in customer acquisition cost (CPA), increased gross margin and a 500% improvement in conversion rate (CVR). These are historical operating metrics; their measurement periods, baselines and definitions will be checked before publication.
What This Demonstrates
Early-stage CEO leadership, investor engagement, multi-channel commercialization, product and scientific innovation, partnership development, and hands-on transformation of a consumer health and bioactive ingredient business.